![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly Receives Third Approval for Breast Cancer Treatment Verzenio
Eli Lilly Receives Third Approval for Breast Cancer Treatment Verzenio
![Eli lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Lilly_Logo.jpg?t=1616695880&width=430)
March 2, 2018
Eli Lilly’s Verzenio (abemaciclib) received FDA approval for a third indication — the combined use with an aromatase inhibitor as an initial endocrine-based therapy to treat postmenopausal women with HR+, HER2- advanced or metastatic breast cancer.
The drug received its initial approval in September, making it the first cyclin-dependent kinase 4 & 6 inhibitor approved for solo and combined use in treating metastatic breast cancer.
The expanded approval was supported by the efficacy and safety results of the MONARCH 3 clinical trial.
Upcoming Events
-
21Oct